Dabigatran for the Prevention of Thromboembolic Complications in the Elderly: A RE-LY-able Alternative to Warfarin?
Keywords: AF = Atrial fibrillation; ARR = Absolute risk reduction; Atrial fibrillation; CAD = Coronary artery disease; CCB = Calcium channel blocker; CCT = Controlled clinical trial; CV = Cardiovascular; Cardiovascular; DM = Diabetes mellitus; Dabigatran; GFR = Glomerular filtration rate; HF = Heart failure; HR = Hazard ratio; HTN = Hypertension; Heart Failure; INR = International normalized ratio; MI = Myocardial infarction; Myocardial infarction; NNT = Number needed to treat; NYHA = New York Heart Association; RE-LY = Randomized Evaluation of Long-Term Anticoagulation Therapy Study; TIA = Transient ischemic attack; VKA = Vitamin K antagonist; Warfarin; cTTR = Centerbased time in therapeutic range
Document Type: Research Article
Publication date: 2012-06-01
- The Consultant Pharmacist® is the official peer-reviewed journal of the American Society of Consultant Pharmacists. It is dedicated exclusively to the medication needs of the elderly in all settings, including adult day care, ambulatory care, assisted living, community, hospice, and nursing facilities. This award-winning journal is a member benefit of ASCP. Individuals who are not members and wish to receive The Consultant Pharmacist® will want to consider joining ASCP.
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- Ingenta Connect is not responsible for the content or availability of external websites